trending Market Intelligence /marketintelligence/en/news-insights/trending/0pT5y-7JtqN1PF9MAjMQcw2 content esgSubNav
In This List

Ampio Pharmaceuticals closes registered direct offering

Blog

Insight Weekly: US bank stress tests; cracks in housing market; summer energy supply risks

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches


Ampio Pharmaceuticals closes registered direct offering

Ampio Pharmaceuticals Inc. closed a registered direct offering of 10,990,245 shares of common stock and warrants to purchase up to 10,990,245 shares of common stock, for gross proceeds of about $6.6 million.

Each unit, priced 60 cents, comprises 1 common share and 1 warrant with an exercise price of 76 cents per share. The warrants are exercisable six months after issuance, and are valid five years after they become exercisable.

The company said it plans to use proceeds for working capital and general corporate purposes, including financing of its Ampion clinical trial.

Joseph Gunnar & Co. LLC and Fordham Financial Management Inc. acted as placement agents for the offering.